CONNECT WITH US:
The University of Tokyo and Eisai Announce Research Collaboration for the Development and Drug Discovery of Targeted Protein Degradation Technology
Oct 08, 2020 13:18 JST
The University of Tokyo and Eisai Co., Ltd. announced today a collaboration aiming for the development and drug discovery of targeted protein degradation technology has been created, with the establishment of a social cooperation program, "Protein Degradation Drug Discovery".
Eisai: Joint Development Agreement Aiming for Drug Discovery for COVID-19 Utilizing Eritoran and E6011 Concluded
Oct 06, 2020 11:07 JST
In patients with COVID-19 due to the SARS-CoV-2 infection, severe cases such as acute respiratory distress syndrome (ARDS) and subsequent multiple organ failure have been reported.
Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea
Sep 30, 2020 14:06 JST
Eisai and Seikagaku signed an agreement for the co-development and marketing alliance in China of SI-613 on April 1, 2020.
Eisai: Jyseleca (Filgotinib) Approved in Japan for Rheumatoid Arthritis
Sep 28, 2020 08:04 JST
Gilead Japan will hold the marketing authorization of Jyseleca in Japan and will be responsible for the product supply of Jyseleca in Japan, while Eisai will be responsible for product distribution of Jyseleca in Japan in RA.
Eisai Receives Positive Opinion from EMA's CHMP on Use of Antiepileptic Agent Fycompa in Pediatric Patients
Sep 23, 2020 08:24 JST
The CHMP's positive opinion is to extend the use of Fycompa as an adjunctive therapy for partial-onset seizures (POS) (with or without secondary generalization) by expanding the approved age range from 12 years and above to 4 years and above, and for primary generalized tonic-clonic seizures (PGTCS) from 12 years and above to 7 years and above.
Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
Sep 23, 2020 08:10 JST
Results from LEAP-004 (Abstract #LBA44) and LEAP-005 (Abstract #LBA41) were accepted as late-breaking abstracts and are being presented in proffered paper presentations at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
Eisai Presents Latest Data of Phase I Clinical Trial on Liposomal Formulation of Anti-Cancer Agent Halaven (Eribulin) at ESMO Virtual Congress 2020
Sep 18, 2020 10:29 JST
Eisai Co., Ltd. has announced that the latest results from the cohort targeting patients with HER2-negative breast cancer in phase I clinical trial for the new liposomal formulation (E7389-LF) of the in-house discovered anti-cancer treatment Halaven were presented (abstract number: 346P) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
Eisai Establishes Pharma Sales Subsidiary in Vietnam
Sep 17, 2020 08:59 JST
Eisai Co., Ltd. announced today that it has established a new pharmaceutical sales subsidiary in Ho Chi Minh City, the Socialist Republic of Viet Nam, which will be named Eisai Vietnam Co., Ltd., Eisai Vietnam is a wholly-owned subsidiary of Eisai.
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2020
Sep 11, 2020 09:41 JST
Eisai Co., Ltd. announced today that a series of abstracts will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19 to 21, 2020.
Eisai to Take over Manufacturing and Marketing Approval for Equfina 50mg Tablets (Safinamide Mesilate) in Japan from Meiji Seika Pharma
Sep 07, 2020 08:02 JST
Eisai Co., Ltd. announced today that it will take over by transfer the manufacturing and marketing approval of Parkinson's disease treatment Equfina 50mg TABLETS (safinamide mesilate, "Equfina") in Japan from Meiji Seika Pharma Co., Ltd., effective September 23, 2020.
Eisai to Launch Sahne Medical Spray and Sahne Medical Cream
Aug 25, 2020 11:55 JST
Eisai conducted a survey of 1,000 women in their 40s to 50s in April 2020. As a result, it was found that approximately 70% of the subjects felt that the dryness of their skin and/or the dry skin expanse had increased compared to its condition five years ago.
Eisai to Present Latest Data of Lemborexant at 34th Annual Sleep Meeting (SLEEP2020)
Aug 25, 2020 09:30 JST
Eisai Co., Ltd. announced today that a total of 10 presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGOTM CIV) will be given at the 34th annual meeting of the Associated Professional Sleep Societies (SLEEP 2020), to be held virtually from August 27 to 30, 2020.
Eisai: Application for Additional Indication of Anti Cancer Agent Lenvima for Unresectable Thymic Carcinoma Submitted in Japan
Jul 31, 2020 08:31 JST
In June 2020, LENVIMA received orphan drug designation in Japan for unresectable thymic carcinoma.
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the Alzheimer's Association International Conference (AAIC) 2020
Jul 22, 2020 16:04 JST
Eisai Co., Ltd. announced today that the company will conduct a total of 9 presentations, including the latest data of the investigational anti-amyloid beta (Aβ) protofibril antibody BAN2401, at the Alzheimer's Association International Conference (AAIC) to be held virtually from July 27 to 31, 2020.
Eisai: Smartphone App for Vital Signs Measurement of Patients With the Novel Coronavirus Infection Experimental Study Project Adopted as AMED Project
Jul 20, 2020 11:36 JST
Allm Inc., Tokyo Medical and Dental University and Eisai Co., Ltd. announced that their jointly submitted study and development project has been selected by the Japan Agency for Medical Research and Development (AMED).
Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease
Jul 14, 2020 08:20 JST
The AHEAD 3-45 will be conducted in the US, Japan, Canada, Australia, Singapore, and Europe.
Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded
Jul 13, 2020 10:47 JST
Eisai Co., Ltd. announced today that it has entered into an industry-academia-government joint research agreement with four universities in Japan concerning the "Industrialization of Japan-originated Toll-like receptor research by Academia-Industry collaborating All-Japan system: Creation of new drug for SLE treatment", which is a research project with Eisai as the representative research organization.
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease
Jul 09, 2020 11:20 JST
Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen has completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of aducanumab, an investigational treatment for Alzheimer's disease.
Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Jul 09, 2020 11:11 JST
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Eisai's and Merck's applications seeking accelerated approval of LENVIMA.
Eisai: New Drug Application for In-House Developed New Anti-insomnia Drug Dayvigo Accepted in Hong Kong
Jul 08, 2020 13:33 JST
Eisai Co., Ltd. announced today that the new drug application for approval of its in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, has been accepted by the Hong Kong Department of Health.
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tazemetostat for EZH2 Gene Mutation-Positive Follicular Lymphoma
Jul 08, 2020 13:16 JST
Eisai Co., Ltd. announced today that it has submitted a marketing authorization application in Japan for the EZH2 inhibitor tazemetostat hydrobromide (generic name, development code: E7438, "tazemetostat") for EZH2 gene mutation-positive follicular lymphoma.
Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan
Jul 06, 2020 08:33 JST
Eisai Co., Ltd. announced today that it has launched its in-house-discovered and developed orexin receptor antagonist DAYVIGO 2.5 mg, 5 mg, 10 mg tablets (lemborexant) for treatment of insomnia in Japan on July 6, 2020.
Eisai: New Fine Granule Formulation of Anti-epileptic Drug Fycompa Launched in Japan
Jul 06, 2020 08:05 JST
Eisai Co., Ltd. announced today that it has launched a new fine granule formulation of its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) in Japan on July 6, 2020.
Remap-Cap to Partner With Eisai on Innovative Trial to Combat COVID
Jul 01, 2020 13:02 JST
The Global Coalition for Adaptive Research (GCAR), in collaboration with UPMC (University of Pittsburgh Medical Center), and Eisai announced today that Eisai will join REMAP-COVID, a substudy of REMAP-CAP (A Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia) that tests multiple interventions for the treatment of patients hospitalized with COVID-19.
Eisai Receives Approval for Parkinson's Disease Treatment Equfina in South Korea
Jun 25, 2020 10:47 JST
Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai's subsidiary in South Korea, has received marketing approval of Parkinson's disease treatment Equfina (safinamide mesilate, "safinamide").
Eisai to Support Counter-Measures Against the Spread of the Novel Coronavirus Infection in Africa
Jun 10, 2020 12:49 JST
Eisai Co., Ltd. announced today that it has committed the equivalent of 1 million USD in aid towards various activities in response to the spread of the novel coronavirus infection in Africa, beginning with the activities described below.
Eisai: Brain Performance (Brain-Health) Self-Check Tool "NouKNOW" to be Used in Beauty Salons
Jun 04, 2020 10:43 JST
Eisai Co., Ltd. announced today that the digital tool for self-assessment of brain performance (brain health) "NouKNOWTM", which Eisai has launched in Japan, is to be expanded in the fixed-rate membership beauty salon "Attina", which is operated by Youforio Co., Ltd.
Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia
Jun 02, 2020 10:05 JST
Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched its in-house discovered orexin receptor antagonist DAYVIGO (lemborexant) CIV for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance in the U.S. on June 1, 2020.
AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody
May 29, 2020 14:54 JST
AbbVie GK and Eisai Co., Ltd. today announced an approval of partial changes in the marketing approval of HUMIRA (generic name: adalimumab [recombinant], hereafter "HUMIRA"), a fully human anti-TNFalpha monoclonal antibody, for additional dosage and administration, specifically, to add an 80mg every-other-week (Q2W) regimen as a treatment option for patients with hidradenitis suppurativa (HS) after the first 4 weeks of treatment.
NEC and Analog Devices Collaborate to provide a 5G O-RAN Massive MIMO Radio for Rakuten Mobile
Oct 23, 2020 17:31 JST
Mitsubishi Power Receives Follow-up Order from Serbia for Two Sets of World's Largest Flue Gas Desulfurization Systems
Oct 22, 2020 18:24 JST
MHI Thermal Systems Opens New Development and Testing Facility for Commercial-Use Air Conditioning & Refrigeration Systems
Oct 22, 2020 18:13 JST
MHI Again Receives EcoVadis Silver Rating for Overall Sustainability
Oct 20, 2020 15:54 JST
Vodafone and NEC Start Trialing Open RAN Technology
Oct 20, 2020 11:09 JST
Mitsubishi Shipbuilding Receives Approval in Principle for LNG Fuel Gas Supply System from Bureau Veritas
Oct 19, 2020 19:07 JST
Supercomputer Fugaku Wins the "Minister of Internal Affairs and Communications Award" at CEATEC 2020 ONLINE
Oct 19, 2020 18:49 JST
Toyota's GR Yaris Makes Its Dynamic Debut at the Goodwood Speedweek
Oct 19, 2020 18:41 JST
Fujitsu Commences Full-Scale Operation of HOKUSAI - SailingShip, RIKEN's New Data Science Infrastructure
Oct 19, 2020 10:39 JST
New ECLIPSE CROSS Reveals Radical New Styling and Expands Plug-In Hybrid Option
Oct 19, 2020 09:45 JST
Honda Announces Completion of the Tender Offer for Shares in Keihin, Showa and Nissin
Oct 16, 2020 17:16 JST
Showa Denko Markets PNVA(TM) 'GE191 Series' for Use as Binder to Form Heat-resisting Ceramic Layer in Separators for LIBs
Oct 16, 2020 16:00 JST
Eisai: Supplementary New Drug Applications for Anti-Epileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures
Oct 16, 2020 13:44 JST
Fujitsu Verifies Effectiveness of Private 5G in Manufacturing Sites in Collaboration with Microsoft Japan
Oct 16, 2020 11:33 JST
Hitachi Acquired Additional Shares to Hold Majority of Shares of Yungtay, Elevator Company Based in Taiwan
Oct 15, 2020 17:41 JST
Mitsubishi Power Signs MOU with Indonesia's PLN Group and Bandung Institute of Technology (ITB) on Joint Policy Proposal to Promote Biomass Co-firing at Thermal Power Plants in Indonesia
Oct 15, 2020 12:06 JST
Hitachi ABB Power Grids Wins $6.6 Million Projects to Digitalize High-Speed Rail in the UK
Oct 14, 2020 17:48 JST
MHI Group Undertakes Investment in HydrogenPro of Norway, Leading Producer of Advanced Electrolyzers
Oct 14, 2020 15:33 JST
Toyota: Launch of a Preparatory Committee for "Japan Hydrogen Association (JH2A)"
Oct 14, 2020 14:06 JST
Fujitsu Accelerates Digital Transformation at Mizuho Bank Branches with Innovative Tablet Solution
Oct 14, 2020 12:58 JST
More Latest Release >>